The use of corticosteroids in patients with severe community pneumonia, bacterial infection which kills lots of patients around the world, reduces the mortality of this infection. However, there are no studies with this type of drug regarding hospital-acquired pneumonia. This is the first multicenter randomized trial to test hydrocortisone plus standard therapy in critical care patients with nosocomial pneumonia. This intervention is inexpensive and may improve the outcome of those patients, besides having an acceptable side effects profile.
18 years of age or older
Suspected ou confirmed case of bacterial nosocomial pneumonia (including ventilator-associated pneumonia)
Intensive Care Unit stay
Signed consent form (by the patient or a legal guardian)
Women who are pregnant, have recently given birth or are breastfeeding
Patients who are moribund or do not have a treatment perspective
Patients with community acquired pneumonia
Patients with other types of pneumonia (viral - including COVID-19, fungal etc.)
Parallel
Hydrocortisone
DrugCorticosteroid
Placebo
DrugNormal saline only
Early Clinical Failure
Composite outcome: Death OR Respiratory worsening OR Cardiovascular worsening
Survival
In the intensive care unit and in the hospital
Respiratory failure
Need for mechanical ventilation
Septic shock
Need for vasoactive drugs
Time of mechanical ventilation
Number of days patients require invasive ventilation support
Click on the lead sponsor to view all of their trials.
Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Collaborator
Hospital de Câncer de Barretos
Collaborator
University of Sao Paulo
Collaborator
